Skip to main content
. Author manuscript; available in PMC: 2019 May 28.
Published in final edited form as: Leukemia. 2018 Feb 22;32(9):1932–1947. doi: 10.1038/s41375-018-0062-8

Fig. 5.

Fig. 5

XBP1-CTL memory cell subset expansion and their increased anti-tumor activities with ACY241 treatment. ACY241 treatment (1 μM) of XBP1-CTL increased the central memory (CD45RO+CCR7+) and decreased the effector memory (CD45RO+CCR7-) cell subsets (Fig. 5a), and it increased CD28 expression and decreased PD1 expression in all of Naive:Memory cell subsets (Fig. 5b). The ACY241 treatment increased anti-tumor activities of XBP1-CTL against myeloma cells (U266), breast cancer cells (MDA-MB231) and colon cancer cells (SW480) (Average + SE; N = 3) (p < 0.05) (Fig. 5c)